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Parkinson’s disease has been traditionally thought of as a dopaminergic disease in which
cells of the substantia nigra pars compacta (SNc) die. However, accumulating evidence
implies an important role for the serotonergic system in Parkinson’s disease in general and
in physiological responses to levodopa therapy, the first line of treatment. We use a math-
ematical model to investigate the consequences of levodopa therapy on the serotonergic
system and on the pulsatile release of dopamine (DA) from dopaminergic and seroton-
ergic terminals in the striatum. Levodopa competes with tyrosine and tryptophan at the
blood-brain barrier and is taken up by serotonin neurons in which it competes for aromatic
amino acid decarboxylase.The DA produced competes with serotonin (5HT) for packaging
into vesicles. We predict the time courses of LD, cytosolic DA, and vesicular DA in 5HT
neurons during an LD dose. We predict the time courses of DA and 5HT release from 5HT
cell bodies and 5HT terminals as well as the changes in 5HT firing rate due to lower 5HT
release. We compute the time course of DA release in the striatum from both 5HT and
DA neurons and show how the time course changes as more and more SNc cells die.
This enables us to explain the shortening of the therapeutic time window for the efficacy
of levodopa as Parkinson’s disease progresses. Finally, we study the effects 5HT1a and
5HT1b autoreceptor agonists and explain why they have a synergistic effect and why they
lengthen the therapeutic time window for LD therapy. Our results are consistent with and
help explain results in the experimental literature and provide new predictions that can be
tested experimentally.
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1. INTRODUCTION
Symptoms of Parkinson’s disease (PD), such as tremor and
bradykinesia, arise following degeneration of dopaminergic cells
within the substantia nigra pars compacta (SNc), depleting
dopamine levels in the basal ganglia. Administration of the
dopamine precursor levodopa (LD) has long been the first line
of treatment for PD; for many patients, LD therapy successfully
relieves symptoms for several years following the initial diag-
nosis. However, within 5 years of chronic LD treatment, many
patients experience a variety of complications (Mouradian et al.,
1988). For instance, the length of the therapeutic time window in
which a given LD dose relieves PD symptoms gradually shortens
and approaches the plasma half-life of LD (wearing-off). Rapid
variations in efficacy may occur (on-off fluctuations). Another,
particularly troubling, complication of chronic LD therapy is
the appearance of involuntary movements (levodopa-induced
dyskinesia, LID). These complications increase patients’ disability
substantially, posea therapeutic dilemma, and limit the use of LD.
Traditionally, PD has been regarded as primarily a dysfunction
of the dopaminergic system in which dopaminergic cells of the SNc
die thereby reducing the amount of dopamine (DA) delivered to
the striatum. However, recent evidence suggests that the interplay
between the serotonergic and dopaminergic systems is critical both
for some symptoms of PD and for understanding the side-effects
of chronic LD therapy. The raphe nuclei (RN) provide dense sero-
tonergic innervation of the striatum, and the basal ganglia projects
back to the RN (Monti, 2010); such reciprocal projections between
basal ganglia and raphe nuclei provide a physical substrate for sero-
tonergic involvement in movement. Interestingly Brooks (2007)
reports that in order to generate tremors with the characteristic
PD frequency of 3–5 Hz in animal models it is necessary to lesion
not just nigro-striatal dopaminergic projections but also the mid-
brain tegmentum, which contains serotonergic cell bodies of the
median raphe. He further notes that loss of midbrain serotonin
5HT1a autoreceptors correlates with tremor severity in PD, unlike
loss of striatal dopaminergic function. Kish et al. (2008) report
that loss of serotonin (5HT) in the striatum is typically both less
severe and more variable than dopamine depletion. The variable
extent of striatal serotonin loss may reflect competing effects such
as raphe cell loss (Jellinger, 1991), molecular regulatory changes
(Kish et al., 2008), and compensatory sprouting of 5HT terminals
(Maeda et al., 2003).
To understand the interesting and complicated relationship of
LD to the serotonergic system, it is useful to briefly sketch the
biochemistry. Cells import tyrosine, tryptophan, and other large
neutral amino acids by the L-transporter (Kilberg and Haussinger,
1992), which also imports LD when it is in the extracellular
space. DA neurons express tyrosine hydroxylase (TH) that converts
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tyrosine to LD, which is decarboxylated by amino acid decarboxy-
lase (AADC) and converted to DA. Most DA does not remain in the
cytosol but is packaged into vesicles by the vesicular monoamine
transporter (VMAT). Since DA does not cross the blood-brain bar-
rier (BBB), its precursor, LD, is given instead, with the intent that
it will be taken up by DA neurons, converted to DA, and increase
the release of DA by the remaining SNc neurons that project to the
striatum. In contrast, 5HT neurons express tryptophan hydrox-
ylase (TPH) that converts tryptophan to 5-hydroxytryptophan
(5HTP) that is decarboxylated by AADC to form 5HT, which is
then packaged into vesicles by VMAT. Thus, it is the differential
expression of TH and TPH that makes neurons into DA neurons
or 5HT neurons, respectively (Feldman et al., 1997). LD interferes
with this distinction because it is taken up by 5HT neurons. And
since the 5HT neurons express AADC and VMAT, the LD in 5HT
neurons is converted to DA, packaged into vesicles, and released
when actions potentials arrive at 5HT terminals. As we will see
below, LD outcompetes 5HTP for AADC and DA outcompetes
5HT for VMAT. The net result is that, during an LD dose, 5HT
neurons release a substantial amount of DA.
There is a lot of evidence that supports this scenario. Experi-
ments have verified that serotonergic cells can store and release DA
in vivo and in vitro (Nicholson and Brotchie, 2002). Tanaka et al.
(1999) showed that, in levodopa treatment of a hemiparkinson-
ian rat, striatal extracellular DA decreased substantially when the
serotonergic system was lesioned. Glial cells also express AADC
and so could contribute to the conversion of LD to DA; however,
experiments by Kannari et al. (2000), in which they used reserpine
to block vesicular packaging, showed a great reduction of extra-
cellular DA, suggesting that most of the levodopa-derived DA is
released by exocytosis of vesicles rather than by glia, at least at phys-
iological levels of levodopa administration. Lindgren et al. (2010)
showed that 5HT1a autoreceptor agonists (that decrease RN fir-
ing) and 5HT1b autoreceptor agonists (that decrease release at
5HT terminals) both lower extracellular DA in the striatum in a
dose-dependent manner after an LD dose.
In addition, there is good evidence that large pulses of extra-
cellular DA are the proximal cause of the levodopa-induced dysk-
inesias (LID) that are seen after long-term dosing with LD (de la
Fuente-Fernandez et al., 2001). Carta et al. (2007) have provided
conclusive evidence that these large pulses of DA are caused by
DA release from serotonergic cells in LID. They showed that either
toxic lesion of the serotonergic system or pharmacological impair-
ment of the system with selective serotonin autoreceptor (5HT1a
and 5HT1b) agonists results in a nearly complete elimination
of LID.
All of these considerations suggest that understanding the
dynamics of LD and DA in 5HT neurons and the interactions
between 5HT neurons and DA neurons in the striatum during an
LD dose are interesting scientific questions with important med-
ical consequences. We have previously constructed mathematical
models of a DA terminal (Best et al., 2009) and a 5HT termi-
nal (Best et al., 2010b) and used the models to explore regulatory
mechanisms, to explain data, and to formulate and test hypotheses
(Best et al., 2009, 2010a, 2011). We have now combined those mod-
els and added a model of the RN cell body. Details of the model
can be found in the Appendix. In this paper, we use the new model
to explore the dynamics of 5HT and DA in 5HT neurons during
an LD dose, and to investigate the dynamics of extracellular DA in
the striatum. We will see how the dynamics change as more cells
in the SNc die and we will see why the therapeutic time window
shortens. Finally, we investigate the effects of 5HT1a and 5HT1b
agonists and show that they decrease the height of the DA pulse
and that they lengthen the therapeutic time window.
2. MATERIALS AND METHODS
The mathematical model used in this paper combines previous
mathematical models of dopaminergic (Best et al., 2009) and sero-
tonergic (Best et al., 2010b) terminals and adds a new model of
the serotonergic cell body in the dorsal raphe nucleus (DRN);
see Figure 1. The dopaminergic terminal model includes: trans-
port of tyrosine across the BBB and into the terminal; synthesis
of LD by tyrosine hydroxylase (TH), synthesis of cytosolic DA by
AADC, packaging of cytosolic DA into vesicles by VMAT, release of
vesicular DA into the extracellular space depending on firing rate,
reuptake of extracellular DA into the cytosol by the dopamine
transporters (DATs), diffusion of extracellular DA out of the sys-
tem, catabolism of DA in both the extracellular space and the
cytosol by monoamine oxidase (MAO), and the effects of extra-
cellular DA on DA synthesis and release via the autoreceptors.
The serotonergic model has the same components except that
tryptophan and tryptophan hydroxylase (TPH) appear instead of
tyrosine and TH, the DATs are replaced by serotonin transporters
(SERTs), and many of the detailed rate constants are different.
The mathematical model of the DRN cell body is similar but
has important differences from the 5HT terminal model. The bio-
chemistry of synthesis of 5HT in the cell body is the same as in
the terminal. However, these 5HT neurons in the DRN have the
interesting property that, when they fire, 5HT is released into the
extracellular space about the cell body and it is also released by
diffusion in the absence of firing (Adell et al., 2002). The extracel-
lular 5HT concentration increases the firing rate when it is low and
decreases the firing rate when it is high via the 5HT1a autorecep-
tors. The firing rate at the cell body affects, of course, the release
of 5HT at the terminal. The extracellular concentration of 5HT in
the striatum affects synthesis and release at the terminal via the
5HT1b autoreceptors.
Tyrosine, tryptophan, and LD are transported across cell mem-
branes by the L-transporter (Kilberg and Haussinger, 1992), which
means that the three substrates compete for transport across the
BBB and for entry into cell bodies and terminals. In addition,
in 5HT cell bodies and terminals, 5-hydroxytryptamine and LD
compete for AADC and 5HT and DA compete for VMAT. Our full
model includes the transport of LD across the BBB and the com-
petition for AADC and VMAT in the 5HT neurons. Full details of
the mathematical formulas that express these competitions can be
found in the Appendix.
3. RESULTS
In Section 3.1 we describe the effects of LD on a 5HT neuron.
In Section 3.2 we discuss the passive stabilization of extracellu-
lar dopamine in the striatum as more and more SNc cells die. In
Section 3.3 we investigate how the increase of extracellular DA in
the striatum after an LD dose depends on the fraction of SNc cells
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FIGURE 1 | A schematic diagram of the major components of the
mathematical model. The model combines previously published models of a
dopaminergic terminal (Best et al., 2009) and a serotonergic terminal (Best
et al., 2010b) in the striatum and adds a model for the serotonergic cell body
in the DRN. See the Discussion in the text. A-5HT and A-DA indicate 5HT and
DA autoreceptors, respectively. Full details are available in the Appendix.
left alive. In Section 3.4 we discuss the effects of 5HT1a and 5HT1b
agonists combined with an LD dose.
3.1. THE EFFECTS OF LD ON 5HT NEURONS
3.1.1. Competition at the blood-brain barrier
LD, tyrosine, and tryptophan are transported across the BBB and
into the extracellular space and from the extracellular space into
neurons and other brain cells by the L-transporter (Kilberg and
Haussinger, 1992). The amino acids and LD compete for the trans-
porter and the affinities of the substrates for the transporter are
different. The net result is that an increase of one of the substrates
in the serum will decrease the transport of the others across the
BBB. Figure 2A shows the effect in the model of an LD dose on
serum levels of LD where we are assuming that the serum lev-
els of tyrosine and tryptophan are constant in the serum at their
normal values. LD has a half-life of about 90 min in the serum
and the curve in Figure 2A is similar to the experimental curves
in Figures 2 and 3 in the paper of Khor and Hsu (2007), where
carbidopa was given with levodopa.
Figure 2B shows the velocities of transport of LD, tyrosine, and
tryptophan across the BBB as a function of time during the dose.
Because of the competition with LD, the transport of tyrosine and
tryptophan decrease during the LD dose. In the rest of this Section
we show the downstream results in 5HT neurons of this LD dose.
Conversely, a protein meal simultaneous with or after an LD
dose will decrease the import of LD into the brain (simulations
not shown). If the transport of LD into the brain varies, one would
expect that extracellular DA in the striatum would vary. It was pro-
posed (Nutt, 1987; Pincus and Barry, 1987) as early as 1987 that
such variation may be one of the causes of the on-off fluctuations
seen clinically in some patients.
3.1.2. Competition for AADC and VMAT
When neurons import LD, the synthesis steps with TH or TPH
are bypassed and the enzyme AADC will convert LD into DA in
both 5HT and DA neurons (see Figure 1). In 5HT neurons, the
cytosolic DA will compete with cytosolic 5HT for VMAT, which
packages 5HT and DA into vesicles. For reasons that we will make
clear, LD outcompetes 5HTP for AADC and DA outcompetes 5HT
for VMAT. The result is that during the LD dose, and for some
time thereafter, the vesicles in 5HT neurons contain substantial
amounts of DA and when the 5HT neuron fires, DA is released as
well as 5HT. In other words, during the LD dose, the 5HT neurons
become (partially) DA neurons.
The red solid curve in Figure 3A shows the cytosolic concen-
tration of LD in the model. The concentration of 5HTP (the solid
blue curve – note the extra factor of 20) is much lower. The intu-
itive reason for this is as follows. Normally, the concentrations
of 5HTP in 5HT neurons and LD in DA neurons are quite low
because they have to be manufactured by THP and TH, respec-
tively, and are quickly decarboxylated. But in supplying LD in
the extracellular space at roughly the concentrations of extracel-
lular tyrosine and tryptophan, the synthesis step is omitted. LD
is imported by the L-transporter directly and will have quite high
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FIGURE 2 | LD competition with tyrosine and tryptophan at the BBB.
(A) Shows the serum levels of a dose of LD; the concentrations of tyrosine
and tryptophan are assumed constant. (B) Shows the transport velocities
of LD, tyrosine, and tryptophan, across the BBB as a function of time.
intracellular concentrations (as seen in Figure 3A). The Km val-
ues of AADC for 5HTP and LD are roughly comparable 160 and
130µM, respectively), so the velocities are determined mostly by
the large difference in concentration between LD and 5HTP dur-
ing the dose. Indeed, the velocity at which cda is being made by
AADC (dashed red curve) in the 5HT neuron is much greater than
the velocity at which 5HT is being made (the dashed blue curve).
One can see from Figure 3A that the velocity at which 5HT is
being made dips during the LD dose because of the competition
with LD.
Because LD outcompetes 5HTP for AADC, during the LD dose,
the concentration of cytosolic DA in the 5HT neuron is much
greater than the concentration of cytosolic 5HT in the 5HT neu-
ron. This can be seen by comparing the solid red (DA) curve to
the solid blue (5HT) curve in Figure 3B. Note that the solid blue
FIGURE 3 | Competition of LD for AADC and VMAT. In (A) the solid blue
curve shows the concentration of 5HTP and the dashed blue curve shows
the rate at which 5HT is being produced during the LD dose. The solid red
curve shows the concentration of LD in the cytosol and the dashed red
curve shows the rate of formation of DA in the 5HT neuron. Note that the
solid blue curve blue has been multiplied by an extra factor of 20. LD
outcompetes 5HTP for AADC because its concentration in the cytosol is
much higher than the concentration of 5HTP. (B) Shows 20 times the
cytosolic concentration of 5HT (solid blue curve) and the cytosolic
concentration of DA (solid red curve). The rate of putting DA into vesicles
(dashed red curve) is much higher than the rate of putting 5HT into vesicles.
See Discussion in the text.
curve is 20 times the concentration of cytosolic 5HT. Because of
this large difference in concentration, DA outcompetes 5HT for
VMAT, the next step in the pathway as shown by the velocities of
VMAT for the two substrates in the dashed red and dashed blue
curves in Figure 3B. This is true even though the Km of 5HT for
VMAT is quite a bit lower than the Km of DA for VMAT (0.2 and
3µM, respectively). As can be seen in Figure 3B, the rate at which
5HT is put into vesicles (the dashed blue curve) dips during the
LD dose because of the competition with DA.
3.1.3. Effect on DA and 5HT in vesicles and 5HT in the striatum
Because the rate at which 5HT is put into vesicles decreases dur-
ing the LD dose, one would expect that vesicular 5HT would also
decrease. This is indeed the case as shown by the blue curve of
Figure 4A. Notice that there is a substantial increase in cytoso-
lic 5HT (the green curve) near the beginning of the LD dose.
There are two reasons for the increase. First, cytosolic 5HT is being
removed and put into vesicles more slowly. Secondly, the rate at
which VMAT puts 5HT into vesicles is partly balanced by diffusion
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FIGURE 4 | Effects of LD on cytosolic, vesicular, and extracellular 5HT.
(A) Shows that vesicular 5HT declines by more than 50% during the LD
dose because of the competition of 5HT and DA for VMAT. The initial rise in
cytosolic 5HT is caused by backflow from the vesicles as vesicular input of
5HT declines. (B) Shows that DA concentration in the vesicles during the
dose is much greater than 5HT concentration. (C) Shows the decline of
extracellular 5HT in the striatum during the LD dose.
of 5HT from the vesicles back into the cytosol. We have included
this diffusive backflow in the 5HT neuron because it is known to
occur in DA neurons efloor95, wallace07. As the forward rate of
VMAT for 5HT drops, backflow from the vesicles contributes to
the temporary rise in cytosolic 5HT.
Figure 4B shows the concentrations of DA (red curve) and 5HT
(blue curve) in the vesicular compartment of the 5HT terminal
during the LD dose. A consequence of LD outcompeting 5HTP for
AADC and DA outcompeting 5HT for VMAT, as described above,
is that during the LD dose more than 80% of the neurotransmitter
in the vesicular compartment of 5HT neurons is DA. Thus, the
5HT neurons are releasing substantially more DA than 5HT.
Figure 4C shows that the concentration of extracellular 5HT in
the striatum (or any other projection region) decreases by about
45% in the model during the LD dose. This is consistent with
experimental results. Borah and Mohanakumar (2007) measured
extracellular 5HTin different brain regions during a dose of LD
and found decreases in the range of 50–90% depending on region.
Tissue 5HT gives an indirect measure of extracellular 5HT because
the amounts released are proportional to storage in vesicles. Carta
et al. (2007) found that tissue 5HT decreases 48% in the striatum
during an LD dose and Navailles et al. (2011) showed that tissue
5HT decreases 30% in the striatum and 53% in motor cortex dur-
ing chronic LD dosing and that 5-HIAA (a metabolite of 5HT)
decreases by 32.
Decreased serotonergic signaling has been linked to depression
(Mann, 1999), so the observation that LD lowers extracellular 5HT
concentrations raises the question of whether LD therapy might
lead to depression. Indeed, acute tryptophan depletion, known
to lower 5HT levels in various brain levels in animals (Moore
et al., 2000), results in lowered mood in humans (Young et al.,
1985). Given the large decreases in brain 5HT levels described
above, one must expect effects on the functioning of the 5HT sys-
tem; however, many complicating factors make it difficult to draw
conclusions about possible connections between LD therapy and
depression (Pålhagen et al., 2008; Frisina et al., 2009). Depression
is frequently described as the most common psychiatric compli-
cation in PD (Lemke, 2008), though reported rates vary widely,
from 2.7% to greater than 90% (Reijnders et al., 2008), due to
factors including whether both major and minor depression are
included and how subjects are selected for inclusion in the study.
Some authors have considered the extent to which depression may
occur in reaction to the burden of this chronic disease, finding
that younger patients, for whom PD may threaten career and
life trajectory, are more vulnerable to depressive responses than
retired patients (Taylor and Saint-Cyr, 1990). The greatest compli-
cation in understanding the occurrence of depression in PD is the
complex nature of depression itself. While many studies support
the hypothesis that impaired serotonergic activity plays a role in
depression, the number of serotonin receptors, transporters, and
the efficacy of serotonin receptor-mediated signal transduction
may be as important as the level of serotonin (Mann, 1999; Best
et al., 2011). Numerous other neurotransmitter systems includ-
ing noradrenaline and dopamine also play significant roles (Remy
et al., 2005; Frisina et al., 2009; Miguelez et al., 2011). Further,
significant deterioration of the serotonergic and noradrenergic
systems may occur with PD (Jellinger, 1991; Halliday and McCann,
2010), often earlier than SNc degeneration (Braak et al., 2003). In
this regard, it is interesting to note that some researchers report that
depression may be an early symptom of the disease (Lemke, 2008;
Poewe, 2008). Finally, we note that, given that LD is a precursor to
both DA and noradrenaline, it is possible that the positive effects
of LD on levels of these neurotransmitters may oppose the poten-
tially depressive effects of lowered 5HT; while mood fluctuations
are often reported in LD-treated PD patients (Black et al., 2005;
Kulisevsky et al., 2007), links between LD therapy and depression
remain equivocal (Mayeux et al., 1984; Taylor and Saint-Cyr, 1990;
Choi et al., 2000; Pålhagen et al., 2008).
3.1.4. Effects on the firing rate of DRN cells
As mentioned above, when the 5HT neurons in the dorsal raphe
nucleus fire they release 5HT from the cell body similarly to the
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release at the terminal. In addition 5HT leaks out from the cell
body into the extracellular space around the cell body and this
accounts for about 30% of the release. The released 5HT binds to
5HT1a autoreceptors which lower firing rate when extracellular
5HT is high and raise firing rate when extracellular 5HT is low.
For a review, see Adell et al. (2002). All three of these effects are in
the model.
Figure 5 shows the extracellular 5HT concentration (blue
curve) and the firing rate of the DRN 5HT neuron as a function of
time during the LD dose. Note that the scale for concentration is at
the left and the scale for firing rate is at the right. In our model the
normal firing rate is 1 spike/s consistent with much experimental
evidence (Gartside et al., 1995; Feldman et al., 1997). During the
main part of the LD dose, the firing rate goes up because extra-
cellular 5HT goes down, a result of less 5HT being released from
vesicles as described in Section 3.1.3. The lower binding to the
5HT1a autoreceptors causes firing rate to go up. But, what is the
reason for the short drop in firing rate near the beginning of the LD
dose? Recall that backflow from the vesicles causes cytosolic 5HT
to increase during the initial part of the dose (the green curve in
Figure 4A). The increase of cytosolic 5HT causes more 5HT to leak
out into the extracellular space (the initial rise in the blue curve in
Figure 5), which lowers the firing rate via the autoreceptors in the
initial phase of the dose.
Finally we note that the increase in firing rate of DRN cells
during the LD dose partially compensates for the drop in vesicular
5HT caused by competition with LD. If the firing rate did not go
up, the drop in striatal extracellular 5HT would be larger than the
45% reported above.
3.2. PASSIVE STABILIZATION OF EXTRACELLULAR DA
An interesting and important feature of PD is that symptoms do
not appear until a very large percentage (60–90%) of the cells in
the SNc have died. Experiments with animal models (Abercrombie
et al., 1990; Bezard et al., 2001; Dentresangle et al., 2001; Bergstrom
and Garris, 2003) have shown that the DA content of striatal tis-
sue declines proportionally to cell death but that the extracellular
concentration of DA in the striatum remains near normal until
FIGURE 5 | LD changes the firing rate of DRN cells. The 5HT
concentration in the striatum (blue curve) and the firing rate of DRN
neurons (black curve) are shown during an LD dose. The scale for the blue
curve is on the left and the scale for the black curve is on the right.
80% or so of the SNc cells have died. There have been many
proposals to explain the homeostasis of extracellular DA in the
face of SNc death. The simplest explanation was given by Garris
and co-workers (Garris and Wightman, 1994; Garris et al., 1997;
Bergstrom and Garris, 2003): as SNc cells die there is proportion-
ally less DA released into the extracellular space, but the reuptake
rate decreases proportionally because there are fewer DATs, and
therefore the concentration of extracellular DA should remain the
same. Garris refers to this phenomenon as “passive stabilization”
to contrast it to other proposed mechanisms that require active
adaptation. We verified the Garris mechanism by model calcula-
tions in Reed et al. (2009) and explained why extracellular DA
does descend to zero when the fraction of cells remaining alive
gets close to zero. As the DA terminals become more sparse, the
probability of a DA molecule that has escaped from a synaptic cleft
being reabsorbed by another DA terminal gets smaller and smaller.
Figure 6 shows the passive stabilization of extracellular DA in the
full model used in this paper. Passive stabilization explains why
PD symptoms don’t appear until more than 80% of SNc cells have
died. In Section 3.3, we study the effect of LD therapy when the
fraction, f, of SNc cells remaining alive is in the range 0.01–0.2.
3.3. DEPENDENCE OF THE THERAPEUTIC TIMEWINDOW ON SNc CELL
DEATH
The rationale behind LD treatment in Parkinson’s disease is that
by supplying the precursor to DA the remaining SNc terminals
in the striatum will store and release more DA. Typically, in the
early stages of the disease, levodopa treatment is very efficacious
in reducing symptoms for many hours. However, as the disease
progresses the duration of benefit of an LD dose tends to become
shorter and shorter until it approximates the half-life of LD in
the serum (Marsden, 1980;Chase et al., 1987, 1989; Fabbrini et al.,
1988; Mouradian et al., 1988; Papa et al., 1994). It has long been
postulated that the“therapeutic time window” shortens because as
more and more cells in the SNc die, there is less and less capacity
in terminals to store DA in the striatum (Spencer and Wooten,
FIGURE 6 | Extracellular DA concentration as a function of the fraction
of SNc cells alive. The curve shows that the extracellular DA concentration
in the striatum does not fall appreciably until 80% or more of the SNc cells
have died.
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1984; Nutt, 1987). Experiments on rats have confirmed that the
response to an LD dose changes with the degree of the denervation
of the projection from the SNc to the striatum (Abercrombie et al.,
1990).
In order to investigate how the fraction of SNc cells left alive,
f, affects the time course of DA in the striatum, we ran simula-
tions with f= 1 (normal), and f= 0.2, 0.1, 0.05, and 0.01 and the
same LD dose as shown in Figure 2A. The results are shown in
Figure 7A. The red curve shows the time course of the response
for a normal individual. Ponzio et al. (1983) saw an increase by a
factor of 2.5 in normal rats. Lindgren et al. (2010) and Abercrom-
bie et al. (1990) found in normal rats that extracellular DA a little
more than doubles during an LD dose. With our dose, extracellular
DA goes up somewhat less than threefold in a normal individual
(f= 1). The blue curve, corresponding to f= 0.2 (an 80% dener-
vation), goes much higher than the red curve. The reason is that
there are many fewer DATs to take up the DA that is released from
the 5HT neurons. And, for f= 0.1, the green curve, the peak of the
extracellular DA is still higher. However, for f= 0.05, the magenta
curve, the peak gets lower, and for f= 0.01, the cyan curve, the
time course of extracellular DA after an LD dose is quite low, even
below the “normal” red curve.
The reason that the peaks come down when denervation is
almost complete is that much of the released DA leaves the sys-
tem. In our model, DA is lost from the extracellular space by three
mechanisms: (1) it is transported back into the cytosol of DA ter-
minals by the DATs; (2) it is catabolized to form homovanillic
acid; (3) it is “removed” the system, which represents uptake by
glial cells, uptake by blood vessels, or simple diffusion out of the
striatum. In the normal striatum there is a dense innervation by
terminals of SNc neurons, so a DA molecule that escapes from the
synaptic cleft of a particular terminal is very likely to be taken up
by the DATs on a different terminal. However, as the DA termi-
nals become more sparse, the remaining terminals will be much
farther apart, and a given molecule will be much more likely to be
removed by one of the mechanisms in (3). In the model, removal
rate is proportional to the current extracellular DA concentration
with constant of proportionality krem and this constant depends
on f the fraction of SNc cells (i.e., the fraction of DA terminals) left
alive. The correct functional form of this dependence is a difficult
question. For the simulations here, we take krem= ko/f.
Thus there are two competing effects. As f gets smaller, the
smaller number of DATs tends to increase the height of the peak,
but the greater removal from the system tends to lower the peak.
The first effect dominates when f is relatively large, i.e., in the range
0.1–1, and the second effect dominates when f is very small, i.e., in
the range 0.01–0.05.
The curves in Figure 7A show the time course of total extra-
cellular DA in the striatum during an LD dose. But how much
of this extracellular DA comes from DA neurons and how much
from 5HT neurons? The answers can be seen in Figure 7B where
the dashed curves show the contribution of the DA neurons in the
cases f= 1, 0.2, 0.1; for comparison we have regraphed the total DA
curves from Figure 7A. For a normal individual, the DA neurons
contribute about 60% of the DA in the striatum during the dose.
However, when most of the SNc cells have died (f= 0.2, 0.1), the
vast majority of the increase of DA in the striatum comes from
5HT neurons. This is consistent with animal experiments. Tanaka
et al. (1999) and Lindgren et al. (2010) showed that lesioning of
the 5HT projection to the striatum decreases DA substantially in
the striatum during an LD dose and Carta et al. (2007) and Lind-
gren et al. (2010) showed that 5HT autoreceptor agonists decrease
the dyskinesias caused by high pulses of DA in the striatum.
When clinicians and experimentalists refer to the “therapeutic
time window” of an LD dose they mean the amount of time after
the dose that Parkinsonian symptoms are suppressed. Our model
does not include downstream electrophysiological behavior in the
basal ganglia, nor does it include the resulting motor behavior.
Nevertheless, we can make a reasonable assumption about how
to calculate the therapeutic time window in the model. In the
lower left corner of Figure 7A, the flat curves represent the steady
state levels of extracellular DA in the striatum for the different
choices of f. The therapeutic level of extracellular DA necessary
to prevent symptoms must be below the red line (since the nor-
mal patient doesn’t have symptoms) and above the blue line (since
the f= 0.2 patient does have symptoms). We’ll take the therapeutic
level of extracellular DA necessary to prevent symptoms as halfway
between the red and blue line, the dashed black line in Figure 7A.
For each choice of f, the therapeutic time window is then the
amount of time that the extracellular DA curve stays above the
dashed line.
Figure 7C shows the therapeutic time window in the model as
a function of f, the fraction of SNc cells left alive. The therapeu-
tic time window shortens from about 10 h when f= 0.2 to a little
more than 2 h when f= 0.01, close to the half-life of the LD dose in
the blood. This is consistent with many clinical and experimental
observations; see for example Fabbrini et al. (1988) and Olanow
et al. (2006). The shortening of the period of efficacy of the LD
dose is caused both by the reduced capacity of the remaining SNc
to store DA released by 5HT neurons and by the loss of DA from
the system as DA terminals become more sparse.
3.3.1. Pulsatile DA in the striatum and dyskinesias
There is a large amount of clinical and experimental evidence that
large pulses of extracellular DA in the striatum are associated with
dyskinesias. For example, PD patients with dyskinesias have higher
levels of synaptic DA after an LD dose (de la Fuente-Fernandez
et al., 2004). Rats with lesioned SNc projections have higher extra-
cellular DA levels in the striatum if they have dyskinesias (Lindgren
et al., 2010). And, DA agonists themselves can cause dyskinesias
(Rascol et al., 2001). Continuous i.v. infusions of LD cause few
dyskinesias (Mouradian et al., 1987). As we have explained above
(Figure 7A), the primary cause of these high pulses is DA release
by 5HT neurons in the striatum.
We also explained that the height of the pulses increases as PD
progresses and the fraction, f, of SNc cells alive declines from 0.2 to
0.05. This is consistent with the results of Mouradian et al. (1988)
who showed that the dose of LD necessary to cause dyskinesias
declines as PD progresses. They attribute the higher pulse to the
declining ability of the remaining SNc neurons to store the DA
produced from LD (the “storage hypothesis”). Our model calcu-
lations suggest that the pulse gets higher as PD progresses because
fewer and fewer DATs are available to take up the DA released by
5HT neurons.
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FIGURE 7 |The progression of PD affects DA in the striatum and the
therapeutic time window. (A) Shows the time course of extracellular DA
in the striatum for different values of f, the fraction of SNc cells left alive. As
f declines the curves get higher because there are fewer DATs to take up
the DA released by 5HT neurons. However, when f is very small the peaks
decline because removal mechanisms such as catabolism and diffusion
become more important. The dashed black horizontal line in (A) represents
the level of extracellular DA needed in the striatum for anti-Parkinsonian
(Continued)
FIGURE 7 | Continued
effects; see the Discussion in the text. (B) Reproduces the first three
curves from [(A); solid curves, f =1, f =0.2, f =0.1]. The dashed curves in
the same color show the amount of extracellular DA in the striatum that
comes from the DA neurons. For a normal individual (f =1) the DA neurons
contribute approximately 60%, but as SNc cells die (f =0.2, f =0.1) most
of the DA comes from the 5HT neurons. (C) Shows that the amount of time
that extracellular DA stays above the therapeutic level [the dashed black line
in (A)] declines as PD progresses until it becomes approximately 2 h.
However, it is also clear that this is not the whole story. Nutt
et al. (2000) showed that repeated doses of LD are necessary to pro-
duce dyskinesias in rats and denervation is not necessary. Other
studies showed that the response to DA agonists is different in PD
patients on LD compared to LD-naive PD patients (Bravi et al.,
1994;Verhagen Metman et al., 1997), suggesting that LD may cause
post-synaptic changes. Since then a whole host of results, reviewed
in Cenci and Lundblad (2006) and Cenci (2007), have shown that
chronic LD dosing is associated with altered intracellular traf-
ficking of DA and glutamate receptors in striatal cells (Hallett
et al., 2005; Guigoni et al., 2007), altered expression and regulation
of transcription factors in striatal cells (Aubert et al., 2007), and
altered oscillatory synchronization frequencies in the Subthalamic
nucleus and the Globus Pallidus (Foffani et al., 2005; Alonso-Frech
et al., 2006). These downstream changes induced by high pulses of
extracellular DA in the striatum are not part of our current model.
3.4. THE EFFECTS OF 5HT1a AND 5HT1b AGONISTS
The 5HT1a autoreceptors on 5HT cell bodies in the DRN regulate
5HT neuron firing rate, depressing it when extracellular 5HT rises
and raising it when extracellular 5HT falls (Adell et al., 2002). The
5HT1b autoreceptors on 5HT terminals in the striatum down-
regulate 5HT release and synthesis when extracellular 5HT rises
and increase synthesis and release when extracellular 5HT falls
(Adell et al., 2002). A number of recent experimental studies have
explored the effects of giving 5HT1a and/or 5HT1b agonists in
combination with LD in animal models (Bibbiani et al., 2001;
Jackson et al., 2004;Carta et al., 2007, 2008; Lindgren et al., 2010).
Here we study the effects of 5HT1a and 5HT1b agonists using our
mathematical model.
In our model, the agonists affect the autoreceptors in the same
way that increasing the level of 5HT would affect the autoreceptors.
Our dose units for the 5HT1a and 5HT1b agonists are multiples
of the normal extracellular 5HT concentration in the Raphe and
the striatum, respectively. Thus a dose of 3 units of a 5HT1a ago-
nist acts in the same way as raising extracellular 5HT from normal
to 4 times normal. We will conduct our experiments on a model
patient or animal with f= 0.1; thus 90% of the projections from
the SNc to the striatum have been removed.
Figure 8A shows the effect of increasing doses of a 5HT1a ago-
nist and a 5HT1b agonist given together. The higher the agonist
concentration the lower the DA pulse in the striatum after an LD
dose, and the longer the time period over which the LD dose has
an effect. The curves are similar to the curves in Lindgren et al.
(2010), Figure 4A. One can see that the effect of the agonists satu-
rates because the response to 5 units of each agonist (the magenta
curve) is not much different from the response to 3 units. This
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FIGURE 8 |The effects of 5HT agonists on extracellular DA in the
striatum. (A) Shows the time course of extracellular DA in the striatum in
the presence of larger and larger equal doses of 5HT1a and 5HT1b
agonists. The agonists lower the peak and stretch out the tail of the DA
concentration. (B) Shows that the DA peak is lowered much more by
dividing the dose between the agonists instead of giving either agonist
alone. (C) Shows how much the therapeutic time window is increased by
the agonists.
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happens because, in the model, the influence of the autoreceptors
on firing rate, synthesis, and release saturates. Figure 8B shows the
synergistic effect of the two types of agonists observed in Carta
et al. (2007, 2008). Ten units of agonist divided equally between
the two types of agonists lowers the DA pulse much more than
10 units of a single agonist.
The dashed curve in Figures 8A,B is the therapeutic threshold
discussed in Section 3.3. The agonists increase the time above the
therapeutic threshold (C). This is because, in the presence of the
agonists, the 5HT neuron fires more slowly and also releases less
neurotransmitter per action potential. As a result, the DA that has
been synthesized in the 5HT neuron from LD is released from
the terminal in the striatum more slowly. Bibbiani et al. (2001)
showed that the 5HT1a agonist sarizotan increases the time above
the therapeutic threshold in rats. Thus, giving 5HT1a and 5HT1b
agonists has two therapeutic benefits: (1) the DA pulse in the stria-
tum is lower and is therefore less likely to cause dyskinesias as
discussed above; (2) the therapeutic time window becomes longer
(Figure 8C).
4. DISCUSSION
We have used our mathematical model to investigate some bio-
chemical and electrophysiological consequences of dosing with
LD. It has been known for a long time that LD competes with
tyrosine and tryptophan and the other large neutral amino acids
at the BBB; it has even been recommended that LD patients con-
sume low protein meals (Pincus and Barry, 1987; Khor and Hsu,
2007). Less well understood are the facts that tyrosine, tryptophan,
and LD are taken up by all cells and that LD in 5HT neurons com-
petes with 5HTP for AADC and that DA competes with 5HT for
VMAT. We explained in Section 3.1 of Results why LD and DA out-
compete 5HTP and 5HT at these two steps, thus essentially turning
5HT neurons into DA neurons during the dose. In Section 3.2 we
explained the mechanism of passive stabilization of extracellular
DA in the striatum that explains why Parkinsonian symptoms do
not appear until approximately 80% of the cells in the SNc have
died. This mechanism, first proposed by Garris, Wightman, and
co-workers (Wightman and Zimmerman, 1990; Bergstrom and
Garris, 2003) and verified in our model (Reed et al., 2009) is not
well known in the community.
In Section 3.3 we investigated how the time course of extra-
cellular DA in the striatum changes during an LD dose as PD
progresses and more cells in the SNc die. We saw that at first the
DA peaks get higher and narrower as more SNc cells die. This is
because there are fewer and fewer DATs available to take up the DA
released from 5HT neurons. However, when very few SNc cells are
left (below 5%) the peak of the extracellular DA curve comes back
down because the lack of DA terminals makes it less and less likely
that a DA molecule that escapes from a synapse will be taken up
by another terminal before being metabolized or diffusing out of
the system. In our model, the therapeutic time window in which
the LD dose relieves PD symptoms gradually shortens to 2 h as PD
progresses and more and more SNc cells die. There may very well
be other mechanism that contribute to shortening (see below), but
we have shown that the biochemistry of LD in 5HT neurons and
the interplay between release from 5HT terminals and uptake by
DA terminals explains the phenomenon.
In Section 3.4 we used the model to investigate the effects of
5HT1a and 5HT1b agonists. As many experimentalists have found,
the agonists lower the height of the extracellular DA peak in the
striatum (Carta et al., 2007, 2008) and increase the therapeutic
time window of the LD dose (Bibbiani et al., 2001). We also see
the synergistic effect of 5HT1a and 5HT1b agonists given together
(Carta et al., 2007). The underlying reason for the synergy is that
the effects of the agonists are governed by binding to the autore-
ceptors. The binding is not a linear function of concentration but
saturates because there are only finitely many receptors. Thus one
gets more inhibition of DA release from a moderate amount of
both agonists than one gets from a large amount of either.
The problem of dyskinesias induced by LD therapy is extremely
important clinically but very complicated scientifically. Between
the LD dose and the dyskinetic behavior there are four levels of
mechanisms. The first level is the absorption of LD from the gut,
the metabolism in the blood, and the transport across the BBB.
The second level is the biochemistry of LD in 5HT neurons and
the interaction between the DA released from 5HT terminals in
the striatum with the remaining SNc terminals. The third level
encompasses the cellular and gene expression changes in striatal
cells caused by the high pulses of DA released from 5HT neurons.
The fourth level consists of the electrophysiological changes that
are thereby induced in the downstream nuclei of the basal gan-
glia. Our model addresses questions only at the first and second
level. There is lots of biological information but no mathemati-
cal modeling yet at the third level. There is a considerable body
of mathematical work that tries to explain and characterize the
dynamical firing patterns in the downstream nuclei of the basal
ganglia as PD progresses, both before and after deep brain stimu-
lation of the subthalamic nucleus (Terman et al., 2002; Best et al.,
2007; van Albada and Robinson, 2009; Hahn and McIntyre, 2010;
Park et al., 2011).
Even on the first and second levels, which are covered by our
model, there are many biological details that we have not included.
Our model does not include a cell body for the SNc neuron. Lind-
gren et al. (2010) have shown that LD increases extracellular DA
in the SNc and this will presumably lower the firing rate of SNc
cells and therefore lower release in the striatum. This was not
included because our main focus in this paper is on the effects
of LD on 5HT neurons. Many other known phenomena where
not included because we wanted to keep the model as simple as
possible we felt that their effects would be relatively small and
would not affect the main conclusions of this paper. For example,
the SNc sends excitatory projections to the DRN and the DRN
sends inhibitory projections to the SNc (Di Matteo et al., 2008;
Guiard et al., 2008). Lesioning the SNc causes hyperinnervation of
the striatum by 5HT neurons (Maeda et al., 2003). And, finally, the
5HT neurons in the RN send ascending projections to a large num-
ber of different brain regions including medial prefrontal cortex
(mPFC), motor cortex, hypothalamus, hippocampus, amygdala,
and the basal ganglia. And, some of these brain regions, substan-
tia nigra, amygdala, mPFC, and hypothalamus send projections
back to the RN (Monti, 2010). As we have explained, all of these
circuits will be affected by LD doses and thus may influence the
firing rates of RN neurons and therefore the release of DA in the
striatum.
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It is known that SERTs can transport DA and that DATs can
transport 5HT, so it is natural to wonder how these phenom-
ena would affect the basic findings and conclusions in this paper.
DATs transport significant amounts of 5HT only in SERT-deficient
mice where the extracellular concentration of 5HT is very high
(Fox et al., 2008). During an LD dose, the 5HT concentration in
the striatum goes down significantly below normal, so it is very
unlikely that 5HT uptake by DATs would play any role. However,
SERTs can transport significant amounts of DA at concentrations
that are in the same range as the DA concentrations seen in the
striatum during LD doses (Larsen et al., 2011). To test how large
this effect is we added DA transport into 5HT terminals by SERTs
to our model using a Km 100 times larger for DA than for 5HT and
a Vmax 4.5 times higher for DA as found by Larsen et al. (2011).
For a normal individual (f= 1), the addition of this transport
caused almost no change in the time course of extracellular DA
in the striatum (simulation not shown). This is consistent with
the results of Larsen et al. (2011) who found that blockade of the
SERTs increases the in vivo clearance time of DA in the hippocam-
pus but not in the striatum. For an individual with advanced PD
(f= 0.1), the addition of this transport caused a modest (13%)
decrease in the peak value of DA in the striatum during the LD
dose (simulation not shown). Thus, the addition of DA trans-
port by SERTs to the model causes small changes in some of the
curves in Figures 7A,B, but does not affect the basics findings and
conclusions of the paper.
Our model makes predictions about the firing rates of RN cells
that can be checked experimentally. First of all, we predict that
during most of the LD dose the firing rates of RN cells will go
up by approximately 20% (Figure 5). However, we also predict
that at the onset of the dose, the firing rate will will dip down.
In the model this is because the competition of DA and 5HT for
VMAT causes a backflow of 5HT from the vesicles of into the
cytosol. The higher cytosolic 5HT concentrations at the beginning
of the dose cause more leakage of 5HT to the extracellular space
where it inhibits firing via the 5ht1a autoreceptors. Experimen-
tal confirmation would provide strong support for the backflow
out of the vesicles proposed in Floor et al. (1995) and Wallace
(2007).
The purpose of mathematical models is to investigate the causal
relationships between phenomena measured by experimentalists
and seen by clinicians, thereby increasing the understanding of
complex biological systems. To be useful, such models must be
based on real physiology and the creation of such models is not
easy. However, if one has a model that represents (part of) the
underlying physiology well, then in silico experiments are quick
and inexpensive. The model provides a quantitative way of think-
ing about the phenomena being investigated and may suggest new
hypotheses that can be checked by animal experiments. Thus,
modeling is a different tool, which, when combined with animal
experiments and clinical trials, can shed some light on the compli-
cated pharmacological, electrophysiological, and behavioral issues
in PD and LD dosing.
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APPENDIX
A schematic diagram of the most important variables in the mathematical model is given in Figure 1. More detailed diagrams of
dopamine and serotonin metabolism and full names of the enzymes are given in Figure A1 (page 3) and Figure A2 (page 4). Table A1
lists all the variables and their steady state concentrations (page 5). The full set of differential equations are given next (page 6), followed
by a discussion of modeling issues (page 8). Tables A2–A5 give all parameter values in the model (page 12).
The 5HT terminal:
d (bh2)
dt
= VTPH
(
tryp, bh4, eht
)− VDRR (bh2, NADPH, bh4, NADP)
d (bh4)
dt
= VDRR (bh2, NADPH, bh4, NADP)− VTPH
(
tryp, bh4, eht
)
d
(
tryp
)
dt
= VLstryp
(
stryp, styr , sld
)− VTPH (tryp, bh4, eht)
− 400 ·
(
tryp
)
20+ tryp + (0.6) ·
(
tryppool
)− V catabtryp (tryp)
d
(
htp
)
dt
= VTPH
(
tryp, bh4, eht
)− V5AADC (htp, 5ld)
d (cht )
dt
= V5AADC
(
htp, 5ld
)− V5MAT (cht , 5cda, vht )+ VSERT (eht )− V catabcht (cht )
d (vht )
dt
= V5MAT (cht , 5cda, vht )− TautoR (eth) ·
(
RFIRE
(
rinput (t ), reht
)) · (vht )
d (eht )
dt
= TautoR (eth) · (RFIRE (rinput (t ), reht)) · (vht )− VSERT (eht )
− V catabeht (eht )− krem · (eht )
d (hia)
dt
= V catabcht (cht )+ V catabeht (eht )− kcatabhia · (hia)
d
(
tryppool
)
dt
= 400 ·
(
tryp
)
20+ tryp − (0.6) ·
(
tryppool
)− kcatabtryppool · (tryppool)
The 5HT cell body:
d (rbh2)
dt
= VTPH
(
rtryp, rbh4, reht
)− VRDRR (rbh2, NADPH, rbh4, NADP)
d (rbh4)
dt
= VRDRR (rbh2, NADPH, rbh4, NADP)− VRTPH
(
rtryp, rbh4, reht
)
d
(
rtryp
)
dt
= VLstryp
(
stryp, styr , sld
)− VRTPH (rtryp, rbh4, reht)
− 400 ·
(
rtryp
)
20+ rtryp + (0.6) ·
(
rtryppool
)− V catabrtryp (rtryp)
d
(
rhtp
)
dt
= VTPH
(
rtryp, rbh4, reht
)− VRAADC (rhtp, rld)
d (rcht )
dt
= VRAADC
(
rhtp, rld
)− VRMAT (rcht , rcda, rvht )+ VSERT (reht )
− V catabrcht (rcht )− kleak · (rcht − reht )
d (rvht )
dt
= VRMAT (rcht , rcda, rvht )−
(
RFIRE
(
rinput (t ), reht
)) · (rvht )
d (reht )
dt
= (RFIRE (rinput (t ), reht)) · (rvht )− VSERT (reht )− V catabreht (reht )
+ kleak · (rcht − reht )− krem · (reht )
d (rhia)
dt
= V catabrcht (rcht )+ V catabreht (reht )− kcatabrhia (rhia)
d
(
rtryppool
)
dt
= 400 ·
(
rtryp
)
20+ rtryp − (0.6) ·
(
rtryppool
)− kcatabrtryppool (rtryppool)
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The DA terminal:
d (dbh2)
dt
= VTH
(
dtyr , dbh4, dcda, deda
)− VDRR (dbh2, NADPH, dbh4, NADP)
d (dbh4)
dt
= VDRR (dbh2, NADPH, dbh4, NADP)− VTH
(
dtyr , dbh4, dcda, deda
)
d(dtyr)
dt
= VLstyr
(
styr , styrp, sld
)− VTH (dtyr , dbh4, dcda, deda)
− k1 ·
(
dtyr
)+ k−1 · (dtyrpool)− kcatabdtyr · (dtyr)
d (dld)
dt
= VLld
(
sld , styr , stryp
)+ VTH (dtyr , dbh4, dcda, deda)− VdAADC (dld)
d (dcda)
dt
= VdAADC (dld)− VdMAT (dcda, dvda)+ VDAT (deda)− kcatabdcda · (dcda)
d (dvda)
dt
= VMAT (dcda, dvda)− dfire(t ) · (dvda)
d (deda)
dt
= dfire(t ) · (dvda)+ (RFIRE (rinput (t ), reht)) · (5vda)− VDAT (deda)
− V catabdeda (deda)− krem · (deda)
d (dhva)
dt
= kcatabdcda · (dcda)+ V catabdeda (deda)− kcatabdhva · dhva
d
(
dtyrpool
)
dt
= k1 ·
(
dtyr
)− k−1 · (dtyrpool)− kcatabdtyrpool · (dtyrpool)
Other:
d (sld)
dt
= lddose(t )− 0.8 · (sld)
d
(
styr
)
dt
= 0
d
(
stryp
)
dt
= 0
d (5ld)
dt
= VLsld
(
sld , styr , stryp
)− VAADC5ld (5ld , 5htp)
d (5cda)
dt
= VAADC5ld
(
5ld , 5htp
)− VMAT5cda (5cda, cht , 5vda)− kcatab5cda · (5cda)
d (5vda)
dt
= VMAT5cda (5cda, cht , 5vda)−
(
RFIRE
(
rinput (t ), reht
)) · (5vda)
d (rld)
dt
= VLsld
(
sld , styr , stryp
)− VAADCrld (rld , rhtp)
d(rcda)
dt
= VAADCrld(rld , rhtp)− VMATrcda(rcda, rcht , rvda)− kcatabrcda · (rcda)
d (rvda)
dt
= VMATrcda (rcda, rcht , rvda)−
(
RFIRE
(
rinput (t ), reht
)) · (rvda)
DISCUSSION OF KEY MODELING ISSUES
In the differential equations, some terms are given explicitly, but most velocities of enzymes or transporters are indicated by a function
name starting with V followed (in parentheses) by the variables on which the velocity depends. The full model used in this paper
combines our previous models of a dopamine terminal (Best et al., 2009) and a serotonin terminal (Best et al., 2010) with a new model
for the serotonin cell body in the raphe nucleus, as well as new variables and differential equations for LD and DA in the 5HT cell body
and terminal. In the absence of an LD dose, the steady state values for the variables in the DA and 5HT terminals are almost identical
to the steady state values in Best et al. (2009, 2010). Except as indicated below, the functional forms of the velocities and the parameters
in the terminals are exactly the same as in Best et al. (2009, 2010), and we refer the reader to those papers where detailed justifications
are given.
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FIGURE A1 | DA metabolism in a DA terminal. Rectangular boxes
indicate substrates (seeTable A1) and blue ellipses contain the
acronyms of enzymes or transporters: V Ltyr, L-amino acid transporter;
DRR, dihydrobiopterin reductase; TPH, tyrosine hydroxylase; AADC,
aromatic amino acid decarboxylase; MAT, vesicular monoamine
transporter; DAT, DA reuptake transporter; auto, DA autoreceptors;
MAO, monoamine oxidase; COMT, catacholamine methyltransferase.
Removal means uptake by capillaries or glial cells or diffusion out of the
system. InTable A1 various shorter names are used for the dopamine
variables in the dopamine terminal and the variables all start with “d”
to distinguish them from the dopamine variables in the 5HT terminal
and cell body.
Some reactions are given by the standard Michaelis–Menten formulas
V = Vmax [S]
Km + [S] , V =
Vmax [S1] [S2](
KS1 + [S1]
) (
KS2 + [S2]
)
V = V
f
max [S1] [S2](
KS1 + [S1]
) (
KS2 + [S2]
) − V bmax [P1] [P2](
KP1 + [P1]
) (
KP2 + [P2]
)
for unidirectional, one substrate, unidirectional, two substrates, and bidirectional, two substrates, two products, reactions, respectively.
Unless there are special issues, they are not discussed, but parameter values are given in Tables A2–A5, which contain all the parameters
for the full model.
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FIGURE A2 | 5HT metabolism in a 5HT terminal. Rectangular boxes
indicate substrates (seeTable A1) and blue ellipses contain the acronyms of
enzymes or transporters: V Ltryp, L-amino acid transporter; DRR,
dihydrobiopterin reductase; TPH, tryptophan hydroxylase; AADC, aromatic
amino acid decarboxylase; MAT, vesicular monoamine transporter; SERT, 5HT
reuptake transporter; auto, 5HT autoreceptors; MAO, monoamine oxidase;
ALDH, aldehyde dehydrogenase. Removal means uptake by capillaries or glial
cells or diffusion out of the system. InTable A1 various shorter names are
used for the 5HT variables in the 5HT terminal and 5HT cell body. The cell
body names all start with “r.”
Competition for enzymes and transporters
One new element in the full model is the competition between DA, LD, and 5HT for the L-transporter, AADC, and VMAT, so we begin
with a detailed discussion about how the competition is modeled. Consider the situation where an enzyme (or transporter) is in the
presence of distinct substrates S1, S2,. . ., SN, which it turns into different products, P1, P2,. . ., PN. The enzyme has a different K
(i)
m for
each substrate and may have different dissociation constants, k(i)d . We’ll start with the case N = 2; the generalization will be obvious.
S1 + E
k1

k−1
S1 · E
k(1)d−−→ P1 + E
S2 + E
k2

k−2
S2 · E
k(2)d−−→ P2 + E
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Table A1 | Variables.
Abbreviation Steady state (µM) Full name
5HTTERMINAL
bh2 0.14 Dihydrobiopterin
bh4 0.86 Tetrahydrobiopterin
Tryp 20.1 Tryptophan
Htp 2.23 5-Hydroxytryptophan
Cht 0.50 Cytosolic 5HT
Vht 20.4 Vesicular 5HT
Eht 0.00073 Extracellular 5HT
Hia 5.21 5-Hydroxyindoleacetic acid
Tryppool 143 The tryptophan pool
5HT CELL BODY
rbh2 0.14 Dihydrobiopterin
rbh4 0.86 Tetrahydrobiopterin
Rtryp 20.1 Tryptophan
Rhtp 2.23 5-Hydroxytryptophan
Rcht 0.49 Cytosolic 5HT
Rvht 20.26 Vesicular 5HT
Reht 0.00097 Extracellular 5HT
Rhia 5.1 5-Hydroxyindoleacetic acid
Rtryppool 143 The tryptophan pool
DATERMINAL
dbh2 0.69 Dihydrobiopterin
dbh4 0.31 Tetrahydrobiopterin
Dtyr 126.9 Tyrosine
Dld 0.36 3,4-Dihyroxyphenylalanine (L-DOPA)
Dcda 2.65 Cytosolic dopamine
Dvda 79.1 Vesicular dopamine
Deda 0.00198 Extracellular dopamine
Dhva 7.68 Homovanillic acid
Dtyrpool 952 The tyrosine pool
OTHER
Sld – Serum levodopa
Styr 63 Serum tyrosine
Stryp 82 Serum tryptophan
5ld – 5HT terminal LD
5cda – 5HT terminal cytosolic DA
5vda – 5HT terminal vesicular DA
Rld – 5HT cell body LD
Rcda – 5HT cell body cytosolic DA
Rvda – 5HT cell body vesicular DA
We make the equilibrium assumption, so:
k1[S1][E] = k−1[S1 · E] and k2[S2][E] = k−2[S2 · E].
Define Etot= [E]+ [S1·E]+ [S2·E] Then,
V1 = dP1
dt
= k(1)d [S1 · E] =
k4Etot
(
k1
k−1
)
[S1] [E]
Etot
=
k(1)d Etot
(
k1
k−1
)
[S1] [E]
[E]+ [S1 · E]+ [S2 · E]
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Table A2 | Kinetic parameters (µM, µM/h, /h): 5HT terminal.
Velocity Parameter Model value Literature value Reference
V AADChtp Aromatic amino acid decarboxylase
K 5htpm 160 160 Sumi et al. (1990)
K 5ldm 130 130 Siaterli et al. (2003)
Vmax 400 *
VDRR Dihydropteridine reductase
K bh2m 100 4–754 Armarego et al. (1986), Bailey and Ayling (1983)
KNADPHm 75 29–770 Firgaira et al. (1981, 1987), Schomburg and Schomburg (2005)
V fmax 5000 *
K bh4m 10 1.1–17 Craine et al. (1972), Firgaira et al. (1981)
KNADPm 75 29–770 Firgaira et al. (1981, 1987), Schomburg and Schomburg (2005)
V bmax 3 *
V Lstryp Neutral amino acid transporter
K strypm 15 15 Kilberg and Haussinger (1992)
K styrm 64 64 Kilberg and Haussinger (1992)
K sldm 32 28–102 Hu and Li (2011), Sampaio-Maia et al. (2001)
Vmax 214 *
VMATcht Vesicular monoamine transporter
K chtm 0.2 0.123–0.253 Slotkin et al. (1978), Rau et al. (2006)
K 5cdam 3 0.2–10 Sherman and Henry (1983), Near (1986), Volz et al. (2006)
Vmax 40 *
kout 0.4 *
V SERT Serotonin transporter
Km 0.17 0.05–1 Feldman et al. (1997), Bunin et al. (1998), Daws et al. (2005)
Vmax 4700 *
VTPH Tryptophan hydroxylase
Ktrp 40 40 McKinney et al. (2005)
Kbh4 20 20 McKinney et al. (2005)
Vmax 400 *
Ki (substrate inhibition) 1000 970 McKinney et al. (2005)
CATABOLISM AND DIFFUSION
V catabcht Km 95 94–95 Fowler and Ross (1984), Gottowik et al. (1993)
Vmax 1000 *
V catabeht Km 95 94–95 Fowler and Ross (1984), Gottowik et al. (1993)
Vmax 1000 *
V catabtryp Km 20 *
Vmax 74 *
kcatabtryppool 0.8 *
kcatabhia 1 1 Echizen and Freed (1984)
krem 400 *
*See text.
=
k(1)d Etot
(
k1
k−1
)
[S1] [E]
[E]+
(
k1
k−1
)
[S1] [E]+
(
k2
k−2
)
[S2] [E]
= k
(1)
d Etot [S1](
k−1
k1
)
+ [S1] [E]+
(
k−1
k1
) (
k2
k−2
)
[S2]
= k
(1)
d Etot [S1]
K (1)m
(
1+ [S2]
K (2)m
)
+ S1
,
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Table A3 | Kinetic parameters (µM, µM/h, /h): 5HT cell body.
Velocity Parameter Model value Literature value Reference
V AADCrhtp Aromatic amino acid decarboxylase
K rhtpm 160 160 Sumi et al. (1990)
K rldm 130 130 Siaterli et al. (2003)
Vmax 400 *
V DRR Dihydropteridine reductase
K rbh2m 100 4–754 Armarego et al. (1986), Bailey and Ayling (1983)
KNADPHm 75 29–770 Firgaira et al. (1981, 1987), Schomburg and Schomburg (2005)
V fmax 5000 *
K rbh4m 10 1.1–17 Craine et al. (1972), Firgaira et al. (1981)
KNADPm 75 29–770 Firgaira et al. (1981, 1987), Schomburg and Schomburg (2005)
V bmax 3 *
VMATrcht Vesicular monoamine transporter
K rchtm 0.2 0.123–0.253 Slotkin et al. (1978), Rau et al. (2006)
K rcdam 3 0.2–10 Sherman and Henry (1983), Near (1986), Volz et al. (2006)
Vmax 40 *
kout 0.4 *
V SERT Serotonin transporter
Km 0.17 0.05–1 Feldman et al. (1997), Bunin et al. (1998), Daws et al. (2005)
Vmax 4700 *
VTPH Tryptophan hydroxylase
Krtrp 40 40 McKinney et al. (2005)
Krbh4 20 20 McKinney et al. (2005)
Vmax 400 *
Ki (substrate inhibition) 1000 970 McKinney et al. (2005)
V Lstryp Neutral amino acid transporter
K strypm 15 15 Kilberg and Haussinger (1992)
K styrm 64 64 Kilberg and Haussinger (1992)
K sldm 32 28–102 Hu and Li (2011), Sampaio-Maia et al. (2001)
Vmax 214 *
CATABOLISM AND DIFFUSION
V catabrcht Km 95 94–95 Fowler and Ross (1984), Gottowik et al. (1993)
Vmax 1000 *
V catabreht Km 95 94–95 Fowler and Ross (1984), Gottowik et al. (1993)
Vmax 1000 *
V catabrtryp Km 20 *
Vmax 74 *
kcatabrtryppool 0.8 *
kcatabrhia 1 1 Echizen and Freed (1984)
krem 400 *
kleak 14
*See text.
where we define K (i)m = (k−i/ki). Thus the general formula is:
Vi = k
(1)
d Etot [Si]
K (i)m
(
1+∑j 6=i [Sj ]K (j)m
)
+ [Si])
, (A1)
which is just the formula in Smith’s article in Kilberg and Haussinger (1992). Note that the effect of the competition is to raise the
effective Km of each amino acid.
When an enzyme has different substrates with different velocities, we indicate which velocity by including the substrate name after
the name of the enzyme or transporter. Thus,V Lstyr,V Lstryp, and V Lsld, indicate the velocities at which styr, stryp, and sld are transported
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Table A4 | Kinetic parameters (µM, µM/h, /h): DA terminal.
Velocity Parameter Model value Literature value Reference
V AADC Aromatic amino acid decarboxylase
Km 130 130 Siaterli et al. (2003)
Vmax 10,000 *
V DAT Dopamine transporter
Km 0.2 0.2–2 Jones et al. (1995), Schmitz et al. (2003)
Vmax 8000 *
V DRR Dihydropteridine reductase
K bh2 100 4–754 Armarego et al. (1986), Bailey and Ayling (1983)
KNADPH 75 29–770 Firgaira et al. (1981, 1987), Schomburg and Schomburg (2005)
V fmax 5000 *
Kbh4 10 1.1–17 Craine et al. (1972), Firgaira et al. (1981)
KNADP 75 29–770 Firgaira et al. (1981, 1987), Schomburg and Schomburg (2005)
V bmax 80 *
VMAT Vesicular monoamine transporter
Km 3 0.2–10 Sherman and Henry (1983), Near (1986), Volz et al. (2006)
Vmax 236 *
kout 0.4 *
VTH Tyrosine hydroxylase
Ktyr 46 46 Royo et al. (2004)
Kbh4 60 13 Royo et al. (2004)
Vmax 3500 *
Ki (cda) 110 110 Morgenroth et al. (1976)
Ki (substrate inhibition) 160 160 Royo et al. (2004); 160 Nakashima et al. (1999)
V Lstyr Neutral amino acid transporter
K styrm 64 64 Kilberg and Haussinger (1992)
K strypm 15 15 Kilberg and Haussinger (1992)
K sldm 32 28–102 Hu and Li (2011), Sampaio-Maia et al. (2001)
Vmax 1840 *
tyr↔Tyrpool
k1 6 *
k−1 0.6 *
CATABOLISM AND DIFFUSION
V catabeda Km 3 3.3 Rivett and Roth (1982)
Vmax 30 *
kcatabdtyr 0.2 *
kcatabdcda 10 *
kcatabdhva 3.45 3.45 Karoum et al. (1977), Dedek et al. (1979)
kcatabdtyrpool 0.2 *
krem 400 *
*See text.
into the brain by the L-transporter. Each of these velocities depends on all three variables as shown in formula (1). We note that the
BBB is actually quite complex, consisting of two layers of cells, and that once substrates have passed they are in the extracellular fluid
and will compete again for transport into cells. We simplify this complex process by having a single competitive transport process from
the serum directly into brain cells.
During an LD dose, 5ld and 5ht compete for AADC in the 5HT terminal, and these velocities are indicated by V AADC5htp, V AADC5ld.
In the raphe cell body the velocities are indicated by V AADCrhtp, V AADCrld. And, in the 5HT terminal and raphe cell body, DA and 5HT
compete for the vesicular monoamine transporter, MAT, and the nomenclature is analogous.
The model for the dorsal raphe cell body and the 5HT1a autoreceptor
The second new feature of the full model is a new model for the cell body of the 5HT neuron in the dorsal raphe nucleus. Most of the
model biochemistry in the cell body is identical to the model biochemistry in the terminal in Best et al. (2010). The exceptions are the
competition discussed above, changed parameters for MAT (discussed below), and the 5HT1a autoreceptors of the cell body. These
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Table A5 | Kinetic parameters (µM, µM/h, /h): LD and DA in the 5HT neuron.
Velocity Parameter Model value Literature value Reference
V AADC5ld Aromatic amino acid decarboxylase
K 5ldm 130 130 Siaterli et al. (2003)
K 5htpm 160 160 Sumi et al. (1990)
Vmax 400 *
V AADCrld Aromatic amino acid decarboxylase
K rldm 130 130 Siaterli et al. (2003)
K rhtpm 160 160 Sumi et al. (1990)
Vmax 400 *
V Lsld Neutral amino acid transporter
K sldm 32 28–102 Hu and Li (2011), Sampaio-Maia et al. (2001)
K strypm 15 15 Kilberg and Haussinger (1992)
K styrm 64 64 Kilberg and Haussinger (1992)
Vmax 1750 *
VMAT5cda Vesicular monoamine transporter
K 5cdam 0.2 0.2–10 Sherman and Henry (1983), Near (1986), Volz et al. (2006)
K chtm 3 0.123–0.253 Slotkin et al. (1978), Rau et al. (2006)
Vmax 40 *
kout 0.4 *
VMATrcda Vesicular monoamine transporter
K rcdam 0.2 0.2–10 Sherman and Henry (1983), Near (1986); Volz et al. (2006)
K rchtm 3 0.123–0.253 Slotkin et al. (1978), Rau et al. (2006)
Vmax 196.8 *
kout 0.4 *
Catabolism
kcatab5cda 10 *
kcatabrcda 10 *
5HT neurons have the unusual property that when the cell fires an action potential, 5HT is not only released at the synapse but also is
released from varicosities and the cell body (Adell et al., 2002). In addition, simple diffusion of 5HT from the cytosol to the extracellular
space accounts for approximately 30% of the released 5HT at the cell body (Adell et al., 2002). Therefore, we include a simple linear
diffusion term in the differential equations for rcht and reht with rate constant kleak chosen so that the leakage release is 30% of total
release at the cell body when the neuron is firing tonically at 1 Hz.
Extracellular 5HT (reht) at the cell body binds to 5HT1a auroreceptors. As reht goes up, the synthesis rate, V TPH declines. We use
the same functional form for this inhibition as in Best et al. (2010) for the way that the 5HT1B autoreceptors affect synthesis in the
terminal. As reht goes up the 5HT1a autoreceptors cause the firing rate to decline. We model this with the formula:
RFIRE (reht ) = 1.5 − (reht )
2(
(.001)2 + (reht )2) ,
so that when reht equals 1 nanomolar (a typical concentration) the firing rate is 1 Hz and when reht goes up firing can become as slow
as 0.5 Hz. We note that the 5HT cell body affects the 5HT terminal through the term RFIRE.
The effect of eht in the striatum on synthesis and release in the 5HT terminal is modeled as in Best et al. (2010). The effect of eda in
the striatum on DA synthesis via the DA autoreceptors is modeled as in Best et al. (2009).
Serum concentrations of tyr, tryp, and LD
For the full model we take the serum concentrations to be styr = 63µM and stryp= 81µM as given in Kilberg and Haussinger (1992).
We adjusted the Vmax values so that the fluxes into the brain (in the absence of an LD dose) are VLtyr= 248µM/h and VLtryp= 151µM/h
as found in Kilberg and Haussinger (1992). The LD dose in the serum is modeled as indicated in Figure 1. The half-life of the dose is
approximately 90 min as is found experimentally (Khor and Hsu, 2007), and we choose the size of the dose so the serum concentration
of LD is comparable to the serum concentrations of tyr and tryp consistent with the clinical and experimental literature (Morris et al.,
1976; Rinne and Molsa, 1979; Hutton et al., 1988; Meuller et al., 2005; Khor and Hsu, 2007). We note that the actual LD dose in the
serum depends on variable transport from the gut and the presence or absence of an AADC inhibitor, as well the size of the dose itself.
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Not surprisingly, the size of changes seen in the model during an LD dose (for example, the drop of eht in the striatum) depends on
the size of the dose.
The Blood-brain barrier
We take the Km of the L-transporter for tyr to be 64µM and the Km for tryp to be 15µM as reported in Kilberg and Haussinger (1992).
There are a wide range of values, 10–102µM for the Km for transport of LD into different types of cells (Sampaio-Maia et al., 2001; Hu
and Li, 2011). We chose a value, 32µM, in the lower part of this range. The formulas for V Lstyr, V Lstryp, and V Lsld are given by formula
(1) with the two unnamed substrates being the competitors.
AADC
For aromatic amino acid decarboxylase, we take the Km= 160 M for 5htp (Sumi et al., 1990) and the Km= 130 for ld (Siaterli et al.,
2003). These are the same values used in Best et al. (2009, 2010). Thus, using formula (1), the velocity by which cda is made from 5ld
in the 5HT terminal is
V5dAADC
(
5ld , 5htp
) = V (1)max (5ld)
(130)
(
1+ (5htp)160
)
+ (5ld)
,
and the velocity by which cht is made from 5htp in the 5HT terminal is
V5AADC
(
5htp, 5ld
) = V (2)max (5htp)
(160)
(
1+ (5ld)130
)
+ (5htp) .
MAT
For the monoamine transporter, we take the Km= 0.2µM for 5ht (Slotkin et al., 1978; Rau et al., 2006) and the Km= 3µM for cda
(Sherman and Henry, 1983; Near, 1986; Volz et al., 2006). These are the same values used in Best et al. (2009, 2010). Thus, thenet
velocity at which cda is packaged into vesicles in the 5HT terminal is
VMAT5cda (5cda, 5ht ) = V
(1)
max (cda)
(3)
(
1+ (5ht )3
)
+ (5cda)
− kout (5vda) ,
and the net velocity at which 5ht is packaged into vesicles in the 5HT terminal is
VMATcht (5ht , 5cda) = Vmax (5ht )
(0.2)
(
1+ (5cda).2
)
+ (5ht )
− kout (5vht ) .
The terms−kout(5vda) and−kout(5vda) represent backleak out of the vesicles as described in Floor et al. (1995) and Wallace (2007)
and here is the only substantial difference between the parameters in the full model for this paper and the parameters for the two termi-
nal models, Best et al. (2009, 2010). The net flux into the vesicular compartment and the release into the extracellular space determine
the concentration (of 5HT or DA) in the cytosolic and vesicular compartments. Since we had a good idea about those concentrations,
we knew well what the net flux ought to be. However, we had no way a gaging what the in and out fluxes should be. When we started
experimenting with the full model in this paper, the LD dose stimulated instantaneous leakage fluxes that were unphysiological. We
therefore lowered both the Vmax in the forward direction and the kout in the backward direction substantially. All parameters for the
full model can be found in Tables A2–A5.
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